James M. Angelastro
Affiliations: | University of California, Davis, Davis, CA |
Area:
Neuroscience Biology, PharmacologyGoogle:
"James Angelastro"Mean distance: 53433
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Banerjee D, Bobolla S, Okochi S, et al. (2023) Activating Transcription Factor 5 (ATF5) Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance. Cancer Research Communications |
Hua ZY, Hansen JN, He M, et al. (2020) PRMT1 promotes neuroblastoma cell survival through ATF5. Oncogenesis. 9: 50 |
Sun X, Jefferson P, Zhou Q, et al. (2019) Dominant-Negative ATF5 Compromises Cancer Cell Survival by Targeting CEBPB and CEBPD. Molecular Cancer Research : McR |
Allen SA, Datta S, Sandoval J, et al. (2019) Cetylpyridinium chloride is a potent AMP-activated kinase (AMPK) inducer and has therapeutic potential in cancer. Mitochondrion |
Sun X, Angelastro JM, Merino D, et al. (2019) Dominant-negative ATF5 rapidly depletes survivin in tumor cells. Cell Death & Disease. 10: 709 |
Sears TK, Datta S, Cortopassi G, et al. (2019) Abstract 3846: Targeting epigenetic dysregulation in isocitrate dehydrogenase mutant glioblastoma Cancer Research. 79: 3846-3846 |
Sears TK, Angelastro JM. (2017) The transcription factor ATF5: role in cellular differentiation, stress responses, and cancer. Oncotarget. 8: 84595-84609 |
Angelastro JM. (2017) Targeting ATF5 in Cancer. Trends in Cancer. 3: 471-474 |
Wald JH, Hatakeyama J, Printsev I, et al. (2017) Suppression of planar cell polarity signaling and migration in glioblastoma by Nrdp1-mediated Dvl polyubiquitination. Oncogene. 36: 5158-5167 |
York D, Sproul CD, Chikere N, et al. (2017) Expression and targeting of transcription factor ATF5 in dog gliomas. Veterinary and Comparative Oncology |